Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Abstract Anti-TNFα and anti-IL-23 antibodies are highly effective therapies for Crohn’s disease or ulcerative colitis in a proportion of patients. V56B2 is a novel bispecific domain antibody in which a llama-derived IL-23p19-specific domain antibody, humanised and engineered for intestinal protease...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kevin J. Roberts, Marion F. Cubitt, Timothy M. Carlton, Lurdes Rodrigues-Duarte, Luana Maggiore, Ray Chai, Simon Clare, Katherine Harcourt, Thomas T. MacDonald, Keith P. Ray, Anna Vossenkämper, Michael R. West, J. Scott Crowe
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/1e2fe779b63b4101b684f9f331edf0fd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares